Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy

Description: Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct to checkpoint immunotherapy. Both have shown impressive activity in pre-clinical models and clinical studies. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Shared By : AnnualMeeting-SITC2017
Posted on : 03/06/17
Added : 2 years ago
Category : Immunotherapy